Challenges of Land Acquisition for Infrastructure in Kenya
AFRICA HABITAT REVIEW · 23.08.2024 · 19 (2) · 2992-3000
DOI: 10.66563/hjaccd94 ↗Kurz gefasst
Fachartikel in der Zeitschrift AFRICA HABITAT REVIEW, online erschienen am 23.08.2024. Verfasst von Erastus K. Museleku und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Land acquisition for infrastructure development can pose challenges in developing countries. This study explored the challenges faced by landowners impacted by the Kisii-Awendo power wayleave acquisition in Kenya. A descriptive research design was used to target 276 project-affected persons through a stratified random sampling strategy. Findings revealed concerns about inadequate compensation (16.6%), poor communication (14.5%), limitations due to illiteracy (12.5%), and financial constraints (12.1%). These issues highlight the limitations of theoretical frameworks like Neoclassical Economic Theory and Lockean Property Theory in addressing real-world complexities. Recommendations for a more equitable and efficient process include improved communication strategies, financial and legal aid for landowners, transparent compensation practices, and literacy support programs. By implementing these recommendations, land acquisition projects can achieve greater fairness and social justice for affected landowners, facilitating the successful completion of vital infrastructure projects.
Zitieren
APA
Museleku, E. K., & Mutinda, J. K. (2024). Challenges of Land Acquisition for Infrastructure in Kenya. AFRICA HABITAT REVIEW, 19(2), 2992-3000. https://doi.org/10.66563/hjaccd94
Vancouver
Museleku EK, Mutinda JK. Challenges of Land Acquisition for Infrastructure in Kenya. AFRICA HABITAT REVIEW. 2024;19(2):2992-3000. doi:10.66563/hjaccd94
BibTeX
@article{Museleku2024,
author = {Museleku, Erastus K. and Mutinda, Jones K.},
title = {Challenges of Land Acquisition for Infrastructure in Kenya},
journal = {AFRICA HABITAT REVIEW},
year = {2024},
volume = {19},
number = {2},
pages = {2992--3000},
doi = {10.66563/hjaccd94}
}
EUVIMED